Study of cost variation analysis for oral anti-diabetic drugs dispensed in pharmacy

The management of diabetes mellitus requires long-term pharmacological interventions, making the cost of anti-diabetic drugs a critical factor influencing treatment adherence and patient outcomes. In India, particularly in regions like Trichy, Tamil Nadu, significant cost variations in oral anti-diabetic drugs are observed across brands and formulations. In this study aims to analyze the price disparities and their potential implications on healthcare affordability and accessibility. In addition, we evaluate the cost variation among commonly prescribed oral anti-diabetic drugs, including Metformin, Glimepiride, Vegliote, Vildagliptin, and Gliclazide, dispensed in pharmacies in Trichy, Tamil Nadu. A cross-sectional observational study was conducted by collecting retail prices of different brands of oral anti-diabetic drugs from pharmacies in Trichy. The percentage cost variation was calculated to determine the extent of price differences among brands of the same generic formulation. The analysis revealed significant cost variations, with Glimepiride (1 mg) showing the highest disparity (1366%), followed by Metformin (500 mg) at 809% and Vegliote (0.3 mg) at 571%. Vildagliptin (50 mg) and Gliclazide (80 mg) exhibited cost variations of 264.6% and 334.78%, respectively. These discrepancies highlight the coexistence of highly affordable generics alongside premium-priced branded alternatives. The findings emphasize the critical role of policymakers, prescribers, and pharmacists in ensuring equitable access to essential medications for diabetes management in resource-limited settings.